<DOC>
	<DOCNO>NCT01963182</DOCNO>
	<brief_summary>This prospective , non randomize multicenter phase II study , determine feasibility individualize dose irinotecan UGT1A1 polymorphism , patient metastatic colorectal cancer treat FOLFIRI .</brief_summary>
	<brief_title>Individualization Dosage Irinotecan FOLFIRI According Genetic Polymorphism UGT1A1 First Line Treatment Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Colorectal cancer histologically cytologically proven Indication treatment accord FOLFIRI + / bevacizumab cetuximab panitumumab Age &gt; 18 year Presence least one measurable target RECIST Life expectancy &gt; 3 month Satisfactory biological function ( renal , hepatic hematologic ) Affiliation social security scheme ( beneficiary plan ) term Act August 9 , 2004 Patient sign , inform informed consent form Patients childbearing age use effective contraception treatment least three month end treatment irinotecan least six month end treatment bevacizumab , cetuximab panitumumab patient pregnant nursing Patient another pathology deem incompatible entry protocol Prior treatment metastatic Patients take antiepileptic Allergic reaction intolerance irinotecan Heart failure , kidney , bone marrow , liver respiratory Higher bilirubin 1.5 time upper limit normal Significant psychiatric neurological abnormality Infectious syndrome require treatment antibiotic antiviral longterm Patients chronic inflammatory bowel disease / bowel obstruction Contraindication Association St. John 's wort yellow fever vaccine Against Heart indication 5FU Concurrent treatment drug test , participation clinical trial within &lt; 30 day Patient refuse sign consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>